Smart Chemotherapy Gets Smarter: Advances in Antibody-drug Conjugates
Antibody-drug conjugates, or ADCs, have emerged as a significant class of cancer therapies over the past two decades. New...
Progress Against Cancer
Antibody-drug conjugates, or ADCs, have emerged as a significant class of cancer therapies over the past two decades. New...
Antibody-drug conjugates, or ADCs, are increasingly common cancer therapies. But what are they? How do they work? And how...
We highlight some of the many innovations showcased at the inaugural AACR Drug Discovery and Development (AACR D3) conference,...
The AACR D3 edition of “From the Bench” highlights cutting-edge approaches from the meeting that could shape the next...
With seven CAR T-cell therapies approved by the U.S. Food and Drug Administration, this innovative immunotherapy has revolutionized the...
In July, the editors from AACR's 10 peer-reviewed journals highlighted research on AI-driven molecular mapping of pancreatic cancer evolution,...
Cancer immunology expert and former AACR president Elizabeth Jaffee, MD, FAACR, discusses the latest progress in the research on...
Exposure to wildfire smoke may increase the risk of developing several cancers, according to research presented at the AACR...
At the AACR Special Conference on Advances in Malignant Lymphoma, Ronald Levy, MD, FAACR, of Stanford University, discussed how...
The June edition of Editors’ Picks from the AACR journals included studies on targeting neural cross-talk to stop glioblastoma...